Program
yinfenidone
Also written as “HEC585”, “HEC585 dose A” and “HEC585 dose B”.
Its studies are mostly in Idiopathic Pulmonary Fibrosis · Pulmonary Fibrosis, led by Sunshine Lake Pharma.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sunshine Lake Pharma | 83 open or running | phase 3since Jul 2, 2025 | Mar 21, 2017 | Dec 2026phase 2 · NCT05139719 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 21, 2017First study: phase 1 study in Idiopathic Pulmonary FibrosisFirst studyNCT03092102 · 136 enrolled · United States
- Aug 7, 2020Phase 1 study in Idiopathic Pulmonary FibrosisNCT04512170 · 72 enrolled · China
- Sep 18, 2021Phase 2 study in Idiopathic Pulmonary FibrosisNCT05060822 · 270 enrolled · China
- Nov 17, 2021Phase 2 study in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)NCT05139719 · 110 planned · China
- Mar 29, 2022Phase 1 study in Idiopathic Pulmonary FibrosisNCT07588646 · 33 enrolled · China
- May 12, 20222 phase 1 studiesNCT05468346, NCT05383131
- Jul 2, 2025Phase 3 study in Idiopathic Pulmonary FibrosisNCT07082842 · 472 planned · China
Ahead
- Dec 2026Primary completion: phase 2 study in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)NCT05139719
- Jan 15, 2031Primary completion: phase 3 study in Idiopathic Pulmonary FibrosisNCT07082842
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07082842Idiopathic Pulmonary Fibrosis · China | 3 | Recruiting | Jan 15, 2031 | 472 |
| NCT05468346Healthy Volunteer · China | 1 | Completed | Aug 14, 2022 | 6 |
| NCT05383131Idiopathic Pulmonary Fibrosis · China | 1 | Completed | Nov 30, 2021 | 33 |
| NCT07588646Idiopathic Pulmonary Fibrosis · China | 1 | Completed | Nov 30, 2021 | 33 |
| NCT05139719Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF) · China | 2 | Recruiting | Dec 2026 | 110 |
| NCT05060822Idiopathic Pulmonary Fibrosis · China | 2 | Active, not recruiting | Jul 16, 2025 | 270 |
| NCT04512170Idiopathic Pulmonary Fibrosis · China | 1 | Completed | Aug 23, 2021 | 72 |
| NCT03092102Idiopathic Pulmonary Fibrosis · United States | 1 | Completed | Feb 25, 2019 | 136 |
How it is read
Names in the registry
- “HEC585”, 6 entries
- “HEC585 dose A”, 1 entry
- “HEC585 dose B”, 1 entry
- “[14C]-HEC585”, 1 entry
Codes read as this program: HEC585.
Conditions, from the studies’ own filings
- Idiopathic Pulmonary Fibrosis, 6 studies
- Pulmonary Fibrosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.